Hydroxyethyl Starch 130/0.42 versus Ringer's Acetate in Severe Sepsis

Autor: Anne Lene Kjældgaard, Jonathan White, Klaus J. Thornberg, Nicolai Haase, Jørn Wetterslev, Lone Musaeus Poulsen, Morten Steensen, Peter Søe-Jensen, Kristian Rørbæk Madsen, Morten Hylander Møller, Lasse H. Andersen, Gudmundur Klemenzson, Per Winkel, Jørgen Wiis, Anders Perner, Morten H. Bestle, Kristian Strand, Lars Broksø Holst, Robert Winding, Maria Louise Fabritius, Pawel Berezowicz, Lars Quist, Katrin Thormar, Frank Christian Pott, Jeanie M. Elkjær, Jonas B. Nielsen, Asger Bendtsen, Frederik Mondrup, Anne Berit Guttormsen, Jyrki Tenhunen, Anders Aneman, Thea Palsgaard Møller

Publikováno v: Perner, A, Haase, N, Guttormsen, A B, Tenhunen, J, Klemenzson, G, Åneman, A, Madsen, K R, Møller, M, Elkjær, J M, Poulsen, L M, Bendtsen, A O, Winding, R, Steensen, M, Berezowicz, P, Søe-Jensen, P, Bestle, M H, Strand, K, Wiis, J, White, J O, Thornberg, K J, Quist, L, Nielsen, J V, Andersen, L H, Holst, L, Thormar, K, Kjældgaard, A-L, Fabritius, M L, Mondrup, F, Pott, F C, Møller, T P, Winkel, P, Wetterslev, J & 6S Trial Group 2012, ' Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis ', The New England Journal of Medicine, vol. 367, no. 2, pp. 124-34 . https://doi.org/10.1056/NEJMoa1204242

A B S T R AC T Background Hydroxyethyl starch (HES) is widely used for fluid resuscitation in intensive care units (ICUs), but its safety and efficacy have not been established in patients with severe sepsis. Methods In this multicenter, parallel-gro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::314e24795dbb1a9583c1051d8078bfef
https://doi.org/10.1056/nejmoa1204242

Lower versus higher hemoglobin threshold for transfusion in septic shock

Autor: Lars B, Holst, Nicolai, Haase, Jørn, Wetterslev, Jan, Wernerman, Anne B, Guttormsen, Sari, Karlsson, Pär I, Johansson, Anders, Aneman, Marianne L, Vang, Robert, Winding, Lars, Nebrich, Helle L, Nibro, Bodil S, Rasmussen, Johnny R M, Lauridsen, Jane S, Nielsen, Anders, Oldner, Ville, Pettilä, Maria B, Cronhjort, Lasse H, Andersen, Ulf G, Pedersen, Nanna, Reiter, Jørgen, Wiis, Jonathan O, White, Lene, Russell, Klaus J, Thornberg, Peter B, Hjortrup, Rasmus G, Müller, Morten H, Møller, Morten, Steensen, Inga, Tjäder, Kristina, Kilsand, Suzanne, Odeberg-Wernerman, Brit, Sjøbø, Helle, Bundgaard, Maria A, Thyø, David, Lodahl, Rikke, Mærkedahl, Carsten, Albeck, Dorte, Illum, Mary, Kruse, Per, Winkel, Anders, Perner, J M, Breider

Publikováno v: Holst, L B, Haase, N, Wetterslev, J, Wernerman, J, Guttormsen, A B, Karlsson, S, Johansson, P I, Aneman, A, Vang, M L, Winding, R, Nebrich, L, Nibro, H L, Rasmussen, B S, Lauridsen, J R M, Nielsen, J S, Oldner, A, Pettilä, V, Cronhjort, M B, Andersen, L H, Pedersen, U G, Reiter, N, Wiis, J, White, J O, Russell, L, Thornberg, K J, Hjortrup, P B, Müller, R G, Møller, M H, Steensen, M, Tjäder, I, Kilsand, K, Odeberg-Wernerman, S, Sjøbø, B, Bundgaard, H, Thyø, M A, Lodahl, D, Mærkedahl, R, Albeck, C, Illum, D, Kruse, M, Winkel, P, Perner, A & TRISS Trial Group 2014, ' Lower versus higher hemoglobin threshold for transfusion in septic shock ', The New England Journal of Medicine, vol. 371, no. 15, pp. 1381-91 . https://doi.org/10.1056/NEJMoa1406617
Holst, L B, Haase, N, Wetterslev, J, Wernerman, J, Guttormsen, A B, Karlsson, S, Johansson, P I, Aneman, A, Vang, M L, Winding, R, Nebrich, L, Nibro, H L, Rasmussen, B S, Lauridsen, J R M, Nielsen, J S, Oldner, A, Pettilä, V, Cronhjort, M B, Andersen, L H, Pedersen, U G, Reiter, N, Wiis, J, White, J O, Russell, L, Thornberg, K J, Hjortrup, P B, Müller, R G, Møller, M H, Steensen, M, Tjäder, I, Kilsand, K, Odeberg-Wernerman, S, Sjøbø, B, Bundgaard, H, Thyø, M A, Lodahl, D, Mærkedahl, R, Albeck, C, Illum, D, Kruse, M, Winkel, P, Perner, A & the TRISS Trial Group and the Scandinavian Critical Care Trials Group 2014, ' Lower versus Higher Hemoglobin Threshold for Transfusion in Septic Shock ', The New England Journal of Medicine, vol. 371, no. 15, pp. 1381-1391 . https://doi.org/10.1056/NEJMoa1406617

BACKGROUND: Blood transfusions are frequently given to patients with septic shock. However, the benefits and harms of different hemoglobin thresholds for transfusion have not been established.METHODS: In this multicenter, parallel-group trial, we ran

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74b1f29c139143ec8ca22bfee88055b4
https://pubmed.ncbi.nlm.nih.gov/27686348

The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients

Autor: Thomas Mohr, J Asger Petersen, Christian Østergaard, Morten Steensen, Anne Øberg Lauritsen, Paul Christian Fjeldborg, Lars Hein, Jesper Kjaer, Jesper Løken, Sine Hougaard, Pernille L. Petersen, Peter Søe-Jensen, Søren Hestad, Lasse H. Andersen, Mads H. Andersen, Klaus J. Thornberg, Katrin Thormar, Teit Mantoni, Peder Carl, Morten H. Bestle, Bettina Lundgren, Jens-Ulrik Stæhr Jensen, Bonnie Bømler, Charlotte Dahl Rossau, Hamid Tousi, Carsten B Thomsen, Kim M Larsen, Jesper Grarup, Jens D Lundgren

Publikováno v: BMC Infectious Diseases
BMC Infectious Diseases, Vol 8, Iss 1, p 91 (2008)
Jensen, J-U, Lundgren, B, Hein, L, Mohr, T, Petersen, P L, Andersen, L H, Lauritsen, A O, Hougaard, S, Mantoni, T, Bømler, B, Thornberg, K J, Thormar, K, Løken, J, Steensen, M, Carl, P, Petersen, J A, Tousi, H, Søe-Jensen, P, Bestle, M, Hestad, S, Andersen, M H, Fjeldborg, P, Larsen, K M, Rossau, C D, Thomsen, C B, Ostergaard, C, Kjaer, J, Grarup, J & Lundgren, J D 2008, ' The Procalcitonin And Survival Study (PASS)-a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients ', B M C Infectious Diseases, vol. 8, pp. 91 . https://doi.org/10.1186/1471-2334-8-91

Background Sepsis and complications to sepsis are major causes of mortality in critically ill patients. Rapid treatment of sepsis is of crucial importance for survival of patients. The infectious status of the critically ill patient is often difficul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a886e45ac1c519be48d084099753484b
https://pubmed.ncbi.nlm.nih.gov/18620598